Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia
Open Access
- 1 November 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. ume 14, 5005-5017
- https://doi.org/10.2147/dddt.s280055
Abstract
Purpose: We evaluated the efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with hypertension and hyperlipidemia. Patients and Methods: Eligible patients, after more than 4 weeks of therapeutic lifestyle change, were randomly assigned to three groups: 5 mg nebivolol plus 20 mg rosuvastatin (NEBI/RSV), 20 mg rosuvastatin (RSV), or 5 mg nebivolol (NEBI). Treatments lasted 8 weeks. Results: Efficacy was analyzed using data from 276 patients. Sitting systolic and diastolic blood pressures differed between the NEBI/RSV and RSV groups (LSmean difference = − 5.89 and − 5.99 mmHg; 95% confidence interval [CI] = − 9.88 to − 1.90 mmHg and − 8.13 to − 3.84 mmHg, respectively). Reductions in the two pressures did not differ between the NEB/RSV and NEB groups. The percent reduction in low-density lipoprotein (LDL) cholesterol differed between the NEBI/RSV and NEBI groups (LSmean difference = − 47.76%, 95% CI = − 52.69 to − 42.84%) but not between the NEBI/RSV and RSV groups. The blood pressure (BP) control rate was higher in the NEBI/RSV group than in the RVS group (51.09% vs 29.67%, p = 0.003). The LDL cholesterol goal achievement rate was higher in the NEBI/RSV group than in the NEBI group (85.87% vs 11.83%, p < 0.001). The incidence of adverse drug reactions in the NEBI/RSV, RSV, and NEBI groups was 8.51%, 7.45%, and 8.60%, respectively (p = 0.950). Conclusion: Nebivolol plus rosuvastatin treatment is effective in reducing BP and LDL cholesterol levels and is safe in patients with hypertension and hypercholesterolemia without the loss of BP or the LDL cholesterol-lowering effect of each drug. Trial Registration: CRIS registration number KCT0002148.Keywords
This publication has 41 references indexed in Scilit:
- Nebivolol Monotherapy in Younger Adults (Younger Than 55 Years) With Hypertension: A Randomized, Placebo-Controlled TrialThe Journal of Clinical Hypertension, 2013
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Nebivolol: The Somewhat-Different β-Adrenergic Receptor BlockerJournal of the American College of Cardiology, 2009
- Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes TrialEuropean Heart Journal, 2006
- Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])The American Journal of Cardiology, 2006
- Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular riskThe Lancet, 2005
- Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IVJournal of Human Hypertension, 2004
- Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid AtherosclerosisCirculation, 2002
- A dose-response trial of nebivolol in essential hypertensionJournal of Human Hypertension, 1997
- Comparative Effects of a New Cardioselective Beta‐Blocker Nebivolol and Nifedipine Sustained‐Release on 24‐Hour Ambulatory Blood Pressure and Plasma LipoproteinsThe Journal of Clinical Pharmacology, 1992